Lipid Dysregulation in Neurodegeneration

Migration, Crosslink

📖

Lipid Dysregulation in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:51 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-lipid-dysregulation-neur

📖 Wiki Page

mechanism2436 wordssynced 2026-04-02

Lipid Dysregulation in Neurodegeneration

Introduction

The brain is the most lipid-rich organ in the body, with lipids constituting ~50% of its dry weight. Brain lipids serve as structural components of membranes, signaling molecules, energy substrates, and regulators of protein function. Perturbations in lipid homeostasis — including altered cholesterol trafficking, sphingolipid imbalance, phospholipid remodeling, and fatty acid oxidation defects — are now recognized as convergent pathological features across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multiple other neurodegenerative disorders[@di2011]. The discovery that [APOE](/genes/apoe), the strongest genetic risk factor for late-onset AD, encodes a lipid transport protein underscores the centrality of lipid metabolism in neurodegeneration[@liu2013].

Brain Lipid Biology

Cholesterol

The brain contains ~25% of total body cholesterol despite comprising only ~2% of body mass. Brain cholesterol is synthesized entirely de novo by [astrocytes](/cell-types/astrocytes) and [oligodendrocytes](/cell-types/oligodendrocytes) because plasma cholesterol cannot cross the [blood-brain barrier](/brain-regions/blood-brain-barrier) (BBB). Cholesterol is essential for:

...

Lipid Dysregulation in Neurodegeneration

Introduction

The brain is the most lipid-rich organ in the body, with lipids constituting ~50% of its dry weight. Brain lipids serve as structural components of membranes, signaling molecules, energy substrates, and regulators of protein function. Perturbations in lipid homeostasis — including altered cholesterol trafficking, sphingolipid imbalance, phospholipid remodeling, and fatty acid oxidation defects — are now recognized as convergent pathological features across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multiple other neurodegenerative disorders[@di2011]. The discovery that [APOE](/genes/apoe), the strongest genetic risk factor for late-onset AD, encodes a lipid transport protein underscores the centrality of lipid metabolism in neurodegeneration[@liu2013].

Brain Lipid Biology

Cholesterol

The brain contains ~25% of total body cholesterol despite comprising only ~2% of body mass. Brain cholesterol is synthesized entirely de novo by [astrocytes](/cell-types/astrocytes) and [oligodendrocytes](/cell-types/oligodendrocytes) because plasma cholesterol cannot cross the [blood-brain barrier](/brain-regions/blood-brain-barrier) (BBB). Cholesterol is essential for:

Myelin formation: ~80% of brain cholesterol resides in myelin sheaths
Synaptic vesicle cycling: Cholesterol-enriched lipid rafts organize SNARE-mediated fusion machinery
Membrane fluidity and receptor signaling: Lipid rafts concentrate signaling receptors
[Amyloid precursor protein](/proteins/app-protein) (APP) processing: Cholesterol levels modulate gamma-secretase and [BACE1](/genes/bace1) activity in lipid rafts[@simons1998]

Brain cholesterol is eliminated primarily via conversion to 24(S)-hydroxycholesterol (24-OHC) by [CYP46A1](/genes/cyp46a1), a neuron-specific enzyme. 24-OHC freely crosses the BBB and serves as a peripheral biomarker of brain cholesterol turnover[@mast2017].

Phospholipids

Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylinositol (PI) form the structural basis of neuronal membranes. Key roles include:

Signal transduction: PI(4,5)P2 cleavage by phospholipase C generates IP3 and DAG
Synaptic vesicle dynamics: PI(4,5)P2 and PI3P regulate endocytosis and [autophagy](/mechanisms/autophagy)
Plasmalogen antioxidant defense: Vinyl-ether bonds in plasmalogens scavenge [ROS](/proteins/reactive-oxygen-species); plasmalogens are reduced 40–60% in AD brain[@han2001]

Sphingolipids

Sphingolipids — ceramide, sphingomyelin, sphingosine-1-phosphate (S1P), glucosylceramide, and gangliosides — play regulatory roles in neurodegeneration:

Ceramide: Pro-apoptotic; elevated 2–3 fold in AD brain, activated via acid sphingomyelinase (aSMase). Ceramide stabilizes [BACE1](/genes/bace1), increasing amyloidogenic APP processing[@puglielli2003]
Sphingosine-1-phosphate (S1P): Pro-survival signal; the ceramide/S1P balance (the "sphingolipid rheostat") determines cell fate
Gangliosides: GM1 ganglioside binds [amyloid-beta](/proteins/amyloid-beta) on membrane surfaces, serving as a seed for fibril formation; GD3 ganglioside activates autophagy[@yanagisawa1995]
Glucosylceramide: Accumulates in [GBA1](/genes/gba1)-mutant Parkinson's disease, promoting [alpha-synuclein](/proteins/alpha-synuclein) aggregation in a bidirectional pathogenic cycle[@mazzulli2011]

Fatty Acids

Docosahexaenoic acid (DHA): The most abundant omega-3 fatty acid in the brain; promotes synaptogenesis, resolves inflammation via specialized pro-resolving mediators (SPMs), and is reduced in AD brain[@cunnane2009]
Arachidonic acid (AA): Source of pro-inflammatory eicosanoids (prostaglandins, leukotrienes) via [COX](/proteins/cox) and LOX pathways
Very-long-chain fatty acids (VLCFA): Accumulate in peroxisomal disorders (adrenoleukodystrophy) causing demyelination

Mechanisms of Lipid Dysregulation in Neurodegeneration

Mermaid diagram (expand to render)

APOE and Cholesterol Transport

[APOE](/genes/apoe) is the primary cholesterol transporter in the CNS, secreted by astrocytes as lipidated HDL-like particles. The three common isoforms (E2, E3, E4) differ in their lipid binding capacity:

APOE4: Poorly lipidated, less efficient at cholesterol efflux, promotes lipid droplet accumulation in astrocytes and [microglia](/cell-types/microglia-neuroinflammation). APOE4 carriers show accelerated amyloid deposition and impaired clearance of [Aβ](/proteins/amyloid-beta) across the BBB[@liu2013]
APOE2: Enhanced lipid transport, protective against AD (OR ~0.6)
[APOE](/proteins/apoe) and microglia: APOE4 drives microglia toward a lipid-accumulating, pro-inflammatory state (lipid-droplet-associated microglia, LDAM), impairing phagocytosis and Aβ clearance[@marschallinger2020]

Lipid Rafts and APP Processing

Cholesterol- and sphingolipid-enriched membrane microdomains (lipid rafts) concentrate the amyloidogenic processing machinery. [BACE1](/genes/bace1) and [gamma-secretase](/proteins/gamma-secretase) (presenilin complex) are enriched in raft fractions, while non-amyloidogenic α-secretase (ADAM10) resides in non-raft regions. Membrane cholesterol levels directly modulate the balance between amyloidogenic and non-amyloidogenic APP processing[@simons1998].

Sphingolipid Imbalance

The ceramide/S1P ratio acts as a molecular switch:

High ceramide: promotes BACE1 stabilization, tau hyperphosphorylation, mitochondrial dysfunction, and [apoptosis](/mechanisms/apoptosis)
High S1P: promotes neuronal survival, synaptic plasticity, and anti-inflammatory signaling
In AD brain, acid sphingomyelinase (aSMase) is elevated 3-fold, driving ceramide accumulation[@puglielli2003]

Glucocerebrosidase and Synucleinopathies

[GBA1](/genes/gba1) mutations (heterozygous) are the most common genetic risk factor for PD (OR ~5–7). Reduced glucocerebrosidase (GCase) activity leads to glucosylceramide accumulation, which directly promotes alpha-synuclein aggregation. Conversely, alpha-synuclein aggregates inhibit GCase trafficking to lysosomes, creating a self-amplifying pathological cycle[@mazzulli2011][@sidransky2009].

Lipid Droplet Accumulation

Lipid droplet (LD) accumulation in [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia) is an emerging hallmark of neurodegeneration. Single-cell transcriptomics reveals lipid-droplet-associated microglia (LDAM) in aging and AD brain, characterized by upregulated lipid synthesis genes, impaired phagocytosis, and increased pro-inflammatory cytokine secretion[@marschallinger2020]. In [neurons](/cell-types/neurons), LD accumulation triggers ER stress and [ferroptosis](/mechanisms/ferroptosis).

Disease-Specific Lipid Pathology

Alzheimer's Disease

| Lipid Change | Direction | Consequence |
|-------------|-----------|-------------|
| Cholesterol in lipid rafts | ↑ | Enhanced Aβ production |
| Plasmalogens | ↓ 40–60% | Reduced antioxidant defense |
| Ceramide | ↑ 2–3x | BACE1 stabilization, apoptosis |
| Sulfatides | ↓ 90% in early AD | Myelin breakdown |
| 24-OHC (plasma) | ↑ early, ↓ late | Reflects neuronal cholesterol turnover |
| DHA (cortical) | ↓ | Impaired synaptic function, increased inflammation |

Parkinson's Disease

Alpha-synuclein–lipid interaction: Alpha-synuclein is a lipid-binding protein that adopts an alpha-helical conformation on curved membranes (synaptic vesicles). Pathogenic mutations (A30P, A53T) alter lipid binding affinity, promoting aggregation[@fusco2014]
GBA1 pathway: Glucosylceramide and glucosylsphingosine directly seed alpha-synuclein fibrils and impair lysosomal function[@mazzulli2011]
Cardiolipin: This mitochondrial-specific phospholipid is oxidized in PD substantia nigra, impairing Complex I activity
DGKQ: Diacylglycerol kinase theta is a PD GWAS hit, linking DAG/PA signaling to disease risk

Lysosomal Storage Disorders with Neurodegeneration

Over 50 [lysosomal storage disorders](/diseases/lysosomal-storage-disorders) demonstrate that primary lipid storage defects cause neurodegeneration:

Niemann-Pick C (NPC1/NPC2): Endolysosomal cholesterol trafficking failure → progressive cerebellar ataxia and dementia
Gaucher disease (GBA1): Glucocerebrosidase deficiency → glucosylceramide accumulation → parkinsonism
Krabbe disease (GALC): Galactosylceramidase deficiency → psychosine toxicity → demyelination
Fabry disease (GLA): Globotriaosylceramide (Gb3) accumulation → cerebrovascular disease
GM2 gangliosidoses (HEXA/HEXB): Tay-Sachs and Sandhoff diseases → catastrophic neuronal storage

Therapeutic Strategies

Cholesterol-Targeted Approaches

Statins: Epidemiological evidence suggests mid-life statin use may reduce AD risk (HR ~0.7), but clinical trials in established AD have been negative, possibly due to poor BBB penetration[@shepardson2011]
CYP46A1 activation: Efavirenz (repurposed HIV drug) activates CYP46A1 at low doses (50–100 mg/day), enhancing neuronal cholesterol turnover; Phase I trial shows increased 24-OHC levels[@mast2017]
Cyclodextrin: 2-hydroxypropyl-β-cyclodextrin solubilizes cholesterol and activates [TFEB](/proteins/tfeb); FDA-approved for NPC (adrabetadex)

Sphingolipid-Targeted Approaches

Ambroxol: GCase pharmacological chaperone; increases GCase activity in GBA1-PD; Phase II trials underway[@mullin2020]
Venglustat: Glucosylceramide synthase (GCS) inhibitor; substrate reduction therapy for GBA1-PD; Phase II MOVES-PD trial did not meet primary endpoints
Fingolimod (FTY720): S1P receptor modulator; FDA-approved for MS; preclinical neuroprotective effects in AD/PD models via enhanced autophagy and anti-inflammation

LXR Agonists

[Liver X receptor (LXR)](/mechanisms/lxr-signaling-neurodegeneration) activation promotes cholesterol efflux via ABCA1/ABCG1 transporters and increases APOE lipidation:

GW3965 and T0901317: Reduce Aβ levels and improve cognition in AD mouse models but cause hepatic steatosis at therapeutic doses[@zelcer2007]
Brain-selective LXR agonists: Under development to avoid peripheral side effects

Dietary and Nutritional Approaches

DHA supplementation: [Omega-3 fatty acids](/therapeutics/omega-3-fatty-acids-neurodegeneration) may slow cognitive decline in MCI (not established AD); [MAPT](/proteins/tau) trial showed benefit in APOE4 non-carriers
[Mediterranean/MIND diet](/therapeutics/mediterranean-mind-diet-neurodegeneration): Rich in unsaturated fatty acids, polyphenols; reduces AD risk by 35–53%
Plasmalogen supplementation: Oral plasmalogen precursors (scallop-derived) in Phase II trials for AD

External Links

[LIPID MAPS](https://www.lipidmaps.org/) — Lipidomics resources
[PubMed: Brain Lipids AND Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=brain+lipids+neurodegeneration)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Recent Research Updates (2024-2026)

[Alves F et al., Signal Transduct Target Ther (2025 Jan 3)](https://pubmed.ncbi.nlm.nih.gov/39746918/)
[Jung ES et al., Mol Neurodegener (2025 Mar 27)](https://pubmed.ncbi.nlm.nih.gov/40149001/)
[Terao R et al., Cell Rep (2024 May 28)](https://pubmed.ncbi.nlm.nih.gov/38636518/)
[Sun Y et al., Int J Mol Med (2025 Sep)](https://pubmed.ncbi.nlm.nih.gov/40641139/)
[Lu J et al., Transl Neurodegener (2024 Oct 29)](https://pubmed.ncbi.nlm.nih.gov/39468688/)

References

[Di Paolo G, Kim TW, Linking lipids to Alzheimer's disease: cholesterol and beyond (2011)](https://pubmed.ncbi.nlm.nih.gov/21461893/)

[Liu CC, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy (2013)](https://pubmed.ncbi.nlm.nih.gov/23296339/)

[Simons M, Keller P, De Strooper B, et al, Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons (1998)](https://pubmed.ncbi.nlm.nih.gov/9634850/)

[Mast N, Saadane A, Valencia-Olvera A, et al, Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28838313/)

[Han X, Holtzman DM, McKeel DW Jr, Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry (2001)](https://pubmed.ncbi.nlm.nih.gov/11591674/)

[Puglielli L, Ellis BC, Saunders AJ, Bhatt DL, Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis (2003)](https://pubmed.ncbi.nlm.nih.gov/12556469/)

[Yanagisawa K, Odaka A, Suzuki N, Ihara Y, GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease (1995)](https://pubmed.ncbi.nlm.nih.gov/7687176/)

[Mazzulli JR, Xu YH, Sun Y, et al, Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies (2011)](https://pubmed.ncbi.nlm.nih.gov/21700325/)

[Cunnane SC, Plourde M, Pifferi F, et al, Fish, docosahexaenoic acid and Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19474131/)

[Marschallinger J, Iram T, Zardeneta M, et al, Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain (2020)](https://pubmed.ncbi.nlm.nih.gov/31959936/)

[Sidransky E, Nalls MA, Aasly JO, et al, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19846850/)

[Fusco G, De Simone A, Gopinath T, et al, Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour (2014)](https://pubmed.ncbi.nlm.nih.gov/25455030/)

[Shepardson NE, Bhatt DL, Bhatt A, Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies (2011)](https://pubmed.ncbi.nlm.nih.gov/21205579/)

[Mullin S, Smith L, Lee K, et al, Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial (2020)](https://pubmed.ncbi.nlm.nih.gov/31930374/)

[Zelcer N, Khanlou N, Clare R, et al, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors (2007)](https://pubmed.ncbi.nlm.nih.gov/17392515/)

Lipid Droplet Biology in Neurodegeneration

Lipid Droplet Formation and Function

Lipid droplets (LDs) are dynamic organelles storage neutral lipids including triglycerides and cholesterol esters:

Formation — LDs form in the ER when neutral lipids accumulate between the bilayer leaflets
Proteome — LDs are coated with proteins including PLIN family members (PLIN1-5)
Functions — Energy storage, lipid metabolism regulation, lipid signaling
Cellular distribution — Present in all cell types, especially adipocytes, hepatocytes, and increasingly recognized in brain cells

LDAM: Lipid-Droplet-Associated Microglia

Single-cell transcriptomics has revealed a distinct microglial subset characterized by lipid droplet accumulation:

Markers — Increased expression of PLIN2/4, CD36, lipid synthesis genes (FASN, SCD1)
Pro-inflammatory phenotype — Upregulated IL-1β, TNF-α, iNOS
Impaired phagocytosis — Reduced clearance of Aβ and cellular debris
Aging association — More prevalent in aged brain, especially near amyloid plaques
Therapeutic target — Reducing LD accumulation may restore microglial function

Astrocyte Lipid Droplets

Astrocytes also accumulate lipid droplets in neurodegeneration:

Trigger — Accumulation of exogenous lipids (e.g., from apoptotic neurons)
Consequence — Impaired astrocyte support of neuronal metabolism
In neurodegeneration — Observed in AD, PD, and ALS brain tissue

Membrane Lipid Dynamics

Lipid Raft Organization

Lipid rafts are cholesterol- and sphingolipid-enriched membrane microdomains:

Composition — 50% cholesterol, 50% sphingolipids by mass
Size — 10-200 nm domains, dynamic and reversible
Function — Concentrate signaling molecules, organize signal transduction

Membrane Fluidity and Neurodegeneration

Membrane lipid composition directly affects neuronal function:

Cholesterol — Increases order, reduces fluidity
Unsaturated fatty acids — Increase fluidity, susceptible to oxidation
Phospholipid headgroups — Determine protein interactions

Changes in membrane lipid composition contribute to:

Impaired neurotransmitter release
Altered ion channel function
Decreased synaptic vesicle recycling
Enhanced toxic protein aggregation

Omega-3 Fatty Acids and Neuroprotection

DHA in Neuronal Health

Docosahexaenoic acid (DHA, 22:6n-3) is the most abundant omega-3 fatty acid in the brain:

Structural role — Major component of neuronal membrane phospholipids (up to 30% of fatty acids in synaptic phospholipids)
Neuroprotective mechanisms:
Anti-inflammatory via specialized pro-resolving mediators (SPMs)
Synaptogenesis promotion via BDNF expression
Mitochondrial function support
Antioxidant via direct free radical scavenging

EPA and Synaptic Function

Eicosapentaenoic acid (EPA, 20:5n-3) also provides neuroprotection:

Precursor for SPMs — Resolvins, protectins, maresins
Membrane incorporation — Less efficiently incorporated than DHA
Clinical trials — Mixed results for cognitive outcomes

Clinical Evidence

| Trial | Population | DHA Dose | Outcome |
|-------|------------|----------|---------|
| MAPT | 1680 elderly, 3yr | 800 mg/day | Benefit in APOE4- only |
| VITAL | 25871 adults, 5yr | 350 mg EPA+DHA | No cognitive benefit |
| SUZUKI | 142 MCI, 6mo | 720 mg DHA | Improved memory |

Lipid Biomarkers in Neurodegeneration

Blood-Based Lipid Biomarkers

| Biomarker | Disease | Change | Utility |
|-----------|---------|--------|---------|
| 24S-hydroxycholesterol | AD | ↑ early, ↓ late | Neuronal loss |
| Phosphatidylcholines | AD | ↓ | Diagnostic |
| Ceramides | PD | ↑ | Risk marker |
| Plasmalogens | AD | ↓ | Progression |
| Oxysterols | AD | ↑ | Oxidative stress |

CSF Lipid Biomarkers

Amyloid-related lipids — Changes in gangliosides with Aβ pathology
Phospholipid profiles — Distinguish AD from controls
Sphingolipid ratios — Ceramide/S1P as cell death indicator

Emerging Therapeutic Approaches

Gene Therapy for Lipid Metabolism

APOE gene delivery — Increase APOE production in brain
CYP46A1 activation — Enhance brain cholesterol elimination
GBA1 gene therapy — Restore glucocerebrosidase activity

Small Molecule Development

| Target | Drug Class | Development Status |
|--------|------------|---------------------|
| GCase chaperones | Ambroxol, venglustat | Phase II/III |
| S1P receptor modulators | Fingolimod repurposing | Preclinical |
| LXR agonists | Brain-penetrant derivatives | Preclinical |
| CYP46A1 activators | Efavirenz analogs | Phase I |

Lipid-Based Delivery Systems

Liposomes — Encapsulate drugs for targeted delivery
Exosomes — Natural lipid nanoparticles for CNS delivery
Nanoparticles — Lipid-based carriers for BBB penetration

📖 View canonical wiki page →

Related Entities

mechanisms-lipid-dysregulation-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-lipid-dysregulation-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6cc2fe7a0ab1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-lipid-dysregulation-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2788

Outgoing

2965

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lipid Dysregulation in Neurodegeneration

Lipid Dysregulation in Neurodegeneration

Introduction

Brain Lipid Biology

Cholesterol

Lipid Dysregulation in Neurodegeneration

Introduction

Brain Lipid Biology

Cholesterol

Phospholipids

Sphingolipids

Fatty Acids

Mechanisms of Lipid Dysregulation in Neurodegeneration

APOE and Cholesterol Transport

Lipid Rafts and APP Processing

Sphingolipid Imbalance

Glucocerebrosidase and Synucleinopathies

Lipid Droplet Accumulation

Disease-Specific Lipid Pathology

Alzheimer's Disease

Parkinson's Disease

Lysosomal Storage Disorders with Neurodegeneration

Therapeutic Strategies

Cholesterol-Targeted Approaches

Sphingolipid-Targeted Approaches

LXR Agonists

Dietary and Nutritional Approaches

See Also

External Links

Allen Brain Atlas Resources

Recent Research Updates (2024-2026)

References

Lipid Droplet Biology in Neurodegeneration

Lipid Droplet Formation and Function

LDAM: Lipid-Droplet-Associated Microglia

Astrocyte Lipid Droplets

Membrane Lipid Dynamics

Lipid Raft Organization

Membrane Fluidity and Neurodegeneration

Omega-3 Fatty Acids and Neuroprotection

DHA in Neuronal Health

EPA and Synaptic Function

Clinical Evidence

Lipid Biomarkers in Neurodegeneration

Blood-Based Lipid Biomarkers

CSF Lipid Biomarkers

Emerging Therapeutic Approaches

Gene Therapy for Lipid Metabolism

Small Molecule Development

Lipid-Based Delivery Systems

💬 Discussion